SAN FRANCISCO – Orteronel – a non-steroidal selective inhibitor of 17,20-lyase – did not achieve a significant improvement in overall survival in 1099 patients randomised to treatment with this “abiraterone-like” agent in comparison with placebo – though radiographic progression-free survival was improved. This finding at the 2014 ASCO Genitourinary Cancers Symposium was presented by Robert Dreicer MD from the Taussig Cancer Institute, Cleveland Clinic, in Cleveland Ohio. He discussed the clinical implications and noted that research is making progress in this challenging clinical situation.
Dr. Robert Dreicer MD
Taussig Cancer Institute
9500 Euclid Avenue/ R35
Cleveland Clinic, Cleveland
SOURCE: ASCO Genitourinary Cancers Symposium 2014 San Francisco
e.g. Abstract number: 7^
Results from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy (ELM-PC 5 trial).
Web link: http://meetinglibrary.asco.org/content/124293-142